While amyloid-β deposition and phosphorylated tau are major therapeutic targets being tested in recent RCTs [48] or developed [49] for Alzheimer’s disease (AD), vascular, inflammatory, immune, metabolic, and other factors are also involved in pathophysiology of AD/ADRD. This evidence concerns the gene MAPT and Alzheimer disease.